AMENDMENTS TO THE CLAIMS

1. (currently amended) An azabicyclic aryl derivative represented by Formula I



(I)

any of its enantiomers or any mixture of its enantiomers, ~~or a prodrug,~~ or a pharmaceutically-acceptable addition salt thereof, wherein

n is 2 ~~1, 2 or 3~~; and

L' represents a linking group selected from –NH–CO– or –N(alkyl)–CO– ~~-O-, -S-, -CO-, -NR'-, -NR'CO- and -CONR'-; wherein R' represents hydrogen or alkyl; or L' represents the linking group -NY'-; wherein Y' represents formyl, acetyl, propionyl or butanoyl~~; and

A represents furan-2,5-diyl ~~an aromatic mono- or bi-cyclic carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, trihaloalkyl, trihaloalkoxy, cyano, nitro, amino, oxo, carboxy, carbamoyl, alkyl carbamoyl, amido, N-alkyl-amido, N,N-dialkyl-amido, sulfamoyl, phenyl or benzyl~~; and

B represents phenyl ~~a covalent bond (i.e. B is absent); or B represents an aromatic monocyclic carbocyclic or heterocyclic group, optionally substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy-alkyl, alkoxy-alkoxy, cycloalkoxy, cycloalkoxy-alkyl, cycloalkoxy-alkoxy, halo, trihaloalkyl, trihaloalkoxy, cyano, nitro, amino, carboxy, carbamoyl, amido, sulfamoyl and phenyl~~; and

L'' represents a linking group selected from –NH–CO– or –NR''–CO–NR'''– ~~-CO-, -CR''=CR'''-, -C≡C-, -NR''-CO-, -CO-NR''-, -SO2-NR''-, -NR''-SO2-, -NR''-CO-NR'''-~~; wherein R'' and R''', independently of one another, represent hydrogen or alkyl; and

C represents phenyl ~~an aromatic monocyclic and/or polycyclic, carbocyclic and/or heterocyclic group~~, optionally substituted one or ~~more~~ two times with substituents selected from the group consisting of ~~alkyl, cycloalkyl, cycloalkyl alkyl, hydroxy, alkoxy, hydroxyalkoxy, alkoxy alkyl, alkoxy alkoxy, cycloalkoxy, cycloalkoxy alkyl, cycloalkoxy alkoxy,~~ halo, trihaloalkyl, trihaloalkoxy, cyano, nitro, amino, -NH-CO-alkyl, -NH-CO-cycloalkyl, NH-CO-alkenyl, –NH–CO–NH_2, and –NH–CO–NH–alkyl ~~carboxy, carbamoyl, amido, sulfamoyl, phenyl and NR'''' CO-NHR''''', wherein R'''' and R''''', independently of one another, represent hydrogen or alkyl; or L'' represents the linking group NR'' CO NY'' ; wherein R'' represents hydrogen or alkyl; and Y'' represents hydrogen, alkyl, aryl alkyl or heteroaryl alkyl; and C represents hydrogen, alkyl, aryl alkyl or heteroaryl alkyl~~.

2. – 27. (cancelled).

28. (currently amended) The azabicyclic aryl derivative of claim 1 [[27]], which is

(±) 5-(4-Benzoylamino-phenyl)-furan-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;

(±) 5-[4-(4-Nitro-benzoylamino)-phenyl]-furan-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;

(±) 5-[4-(4-Amino-benzoylamino)-phenyl]-furan-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;

(±) 5-[4-(4-Acetylamino-benzoylamino)-phenyl]-furan-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;

(±) 5-[4-(4-Acryloylamino-benzoylamino)-phenyl]-furan-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;

(±) 5-{4-[4-(Cyclopropanecarbonyl-amino)-benzoylamino]-phenyl}-furan-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;

(±) 5-[4-(3-Ethyl-ureido)-phenyl]-furan-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;

(±) 5-[4-(3-Phenyl-ureido)-phenyl]-furan-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;

(±) 5-{4-[3-(4-Nitro-phenyl)-ureido]-phenyl}-furan-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide;

(±) 5-{4-[3-(4-Amino-phenyl)-ureido]-phenyl}-furan-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide; or

(±) 5-{4-[3-(4-Acetylamino-phenyl)-ureido]-phenyl}-furan-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide[[;]],

or an enantiomer or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof.

29. (previously presented) A pharmaceutical composition comprising a therapeutically effective amount of an azabicyclic aryl derivative of claim 1, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.

30. – 38. (cancelled).

39. (cancelled).

40. (new) The azabicyclic aryl derivative of claim 1, wherein

n is 2;

L' represents -NH-CO- or -N(alkyl)-CO-;

A represents furan-2,5-diyl;

B represents phenyl;

L'' represents -NH-CO- or -NH-CO-NH-; and

C represents phenyl, optionally substituted once or twice with substituents selected from halo, trihaloalkyl, trihaloalkoxy, cyano, nitro, amino, acetylamino, cyclopropane-carbonyl-amino, acryloylamino, ureido, and N-alkyl-ureido,

or an enantiomer or a mixture of its enantiomers, or a pharmaceutically-acceptable addition salt thereof.